NEW YORK (Reuters Health) - A single subcutaneous dose of the investigation drug selatogrel, a reversible P2Y12-receptor antagonist, provides a rapid, dose-related antiplatelet response in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback